Leukemia News

Women receiving cancer treatment in clinical trials exhibited higher risk for severe symptomatic and hematologic adverse events than their male counterparts, according to a study.

The FDA announced several regulatory actions the past few weeks.

Mark Cuban Cost Plus Drug Company’s pricing could yield significant savings for seven generic oncology drugs vs. Medicare Part D median formulary prices, according to study results published in Journal of Clinical Oncology.

In this edition, CAR-T trial for leukemia paused after patient death; obesity may increase risk for blood cancer; new CAR T-cell therapies ‘waiting’ for patients with leukemia and more.

Pirtobrutinib appeared effective among a cohort of heavily pretreated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma, according to study results published in The New England Journal of Medicine.

The FDA announced several regulatory actions the past few weeks.

In his new role as president and CEO of The Leukemia & Lymphoma Society, pediatric hematologist oncologist E. Anders Kolb, MD, aims to expand his life’s work in advancing blood cancer research and therapies for patients of all ages.

In this video, Aaron T. Gerds, MD, MS, discussed the results of the phase 3 COMMANDS study, pertaining to low-risk myelodysplastic syndrome, presented at ASCO Annual Meeting.

Obesity appeared strongly associated with clonal hematopoiesis of indeterminate potential — a blood condition linked to increased risk for blood cancer, according to study results published in The Journal of Clinical Investigation.

In this video, Michael Choi, MD, discusses updated data on the results of liso-cel chimeric antigen receptor T-cell treatments on chronic lymphocytic leukemia, presented at ASCO Annual Meeting.